Phytoconstituents holds immense potential as an alternative to synthetic cancer medicines or supplements. Tyrosine kinase inhibitors (TKIs), such as imatinib, have significantly improved outcomes for chronic myeloid leukemia (CML) patients, but overcoming resistance to imatinib remains a major challenge. This study aimed to identify a phytocompound with minimal side effects that could effectively target ABL1 and BCL2 to combat CML. A total of 108 phytocompounds were selected and their potential to inhibit BCL2 and ABL1 kinases were determined using a molecular docking study. Among these, daidzin exhibited significant binding affinity to both BCL2 and ABL1 kinases. To further assess the impact of daidzin over BCL2 and ABL1 kinase upon binding, a molecular dynamics simulation was conducted. Additionally, the apoptosis induction and BCL2 downregulation in imatinib-resistant CML cell lines (K562R) were evaluated in follow-up in-vitro experiments. The MTT assay revealed that the IC50 of daidzin was 51.62 ± 0.70 µM, which was higher than venetoclax IC50 is 32.73 ± 2.88 µM. Apoptosis assay at their respective IC50 concentration showed that daidzin induced 61.53% cell death while venetoclax induced 56.91% cell death in imatinib-resistant K562R cells. Further, both daidzin and venetoclax showed significant downregulation of BCL2 expression, with a reduction of 30.58 ± 0.19% and 36.42 ± 1.53%, respectively, compared to untreated imatinib-resistant K562R cells. These results demonstrate that daidzin is highly effective against imatinib-resistant K562R cell line and leads to significant BCL2 downregulation. However, further comprehensive in-vivo study is necessary to fully validate these findings.